Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB-SAHARAN AFRICA

Project description

Advancing vaccine access for neglected diseases in Africa

Vaccines against neglected tropical diseases (NTDs) are not yet widely available in sub- Saharan Africa. This is mainly because vaccine trials have often been conducted outside the populations most at risk. With this in mind, the EU-funded EAVI project is establishing a European-African vaccine partnership to evaluate the safety and immune response to a Chikungunya vaccine in both healthy adults and people living with HIV. Through a clinical trial, advanced immunological research, enhanced disease surveillance, and capacity building, EAVI aims to generate evidence to support the introduction of vaccines in Africa and establish a platform for the evaluation of vaccines against other NTDs in the future.

Objective

Access to vaccines against neglected tropical diseases (NTDs) is limited in sub-Saharan Africa (SSA), where NTD burdens are high, while vaccine trials often are performed in Western populations. There is an urgent need to test, license and distribute vaccines in SSA populations at risk of NTDs, especially vulnerable groups like those with co-infections. The European-African vaccine initiative (EAVI) closes this gap by developing a European-African vaccine partnership to evaluate the safety, immunogenicity, and efficacy of prophylactic vaccines against NTDs in SSA. As a proof of concept, EAVI will evaluate a live-attenuated Chikungunya virus (CHIKV) vaccine—licensed in EU, Canada, UK, and Brazil—in healthy and in vulnerable HIV-positive adults in Africa. To achieve this, we will: 1. perform a two-armed clinical phase IIIb clinical trial in Kenya and Tanzania with rigorous safety and immunogenicity endpoints; 2. carry out in-depth immune-profiling using gold-standard and beyond state-of-the-art methodology; 3. integrate prevention and surveillance through enhanced diagnostics and One Health prospective serosurvey in humans and vector monitoring; 4. foster technology transfer, capacity building, and training in SSA as well as strategic partnerships for robust stakeholder and community engagement and uptake. EAVI’s multidisciplinary expertise of clinicians, social scientists, statisticians, epidemiologists, immunologists, virologists, and vaccine manufacturers provides proven experience in implementing complex clinical trials in SSA, including in people living with HIV, and the most innovative immune-profiling technologies to leverage the full potential of the trial. It will pave the way toward access of the CHIKV vaccine in SSA to fight this NTD as well as a roadmap for future trials of other NTD vaccines, in healthy, HIV-positive and other vulnerable populations in SSA.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2025-01-two-stage

See all projects funded under this call

Coordinator

MEDIZINISCHE UNIVERSITAT INNSBRUCK
Net EU contribution
€ 3 430 671,25
Address
CHRISTOPH PROBST PLATZ 1
6020 INNSBRUCK
Austria
Region
Westösterreich Tirol Innsbruck
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 3 430 671,25

Participants (7)